Wall Street Associates’s Argos Therapeutics, Inc. ARGS Stock Holding History

Wall Street Associates’s Portfolio ARGS Stock Details ARGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$406K	Sell	4,143 -5,112	-55%	-$478K	0.27%	125
2016 Q3	$920K	Hold	9,255	–	–	0.31%	105
2016 Q2	$1.14M	Sell	9,255 -465	-5%	-$62.1K	0.45%	88
2016 Q1	$1.24M	Sell	9,720 -3,175	-25%	-$257K	0.52%	81
2015 Q4	$596K	Hold	12,895	–	–	0.17%	190
2015 Q3	$1.24M	Sell	12,895 -9,930	-44%	-$1.18M	0.24%	115
2015 Q2	$3.13M	Sell	22,825 -420	-2%	-$67.1K	0.29%	106
2015 Q1	$4.14M	Sell	23,245 -510	-2%	-$88.7K	0.39%	92
2014 Q4	$4.75M	Hold	23,755	–	–	0.46%	82
2014 Q3	$4.78M	Sell	23,755 -2,370	-9%	-$370K	0.49%	79
2014 Q2	$4.2M	Buy	26,125 +235	+0.9%	+$38.9K	0.36%	102
2014 Q1	$5.18M	Buy	+25,890	New	+$5.18M	0.42%	87

Other funds holding ARGS

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wall Street Associates's ARGS Position: Q4 2016 in Review

Wall Street Associates reduced its Argos Therapeutics, Inc. (ARGS) stake by 55% in Q4 2016, selling an estimated $478K and leaving 4,143 shares worth $406K. The position accounts for 0.27% of the portfolio, ranked #125.

Wall Street Associates first reported a position in ARGS in Q1 2014 and has held it in 12 quarters since. The position peaked at $5.18M in Q1 2014. 52 funds tracked by Wall St. Rank hold ARGS as of Q4 2016.

Wall Street Associates held 4,143 shares of Argos Therapeutics, Inc. worth $406K as of Q4 2016.
Wall Street Associates sold 5,112 Argos Therapeutics, Inc. shares in Q4 2016, an estimated $478K.
Argos Therapeutics, Inc. made up 0.27% of Wall Street Associates's portfolio in Q4 2016, its #125 holding.
Wall Street Associates first reported a position in Argos Therapeutics, Inc. in Q1 2014 and has held it in 12 quarters since.
Wall Street Associates's Argos Therapeutics, Inc. position peaked at $5.18M in Q1 2014.
52 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q4 2016.

Based on Wall Street Associates's 13F filing for Q4 2016, filed 18 Jan 2017.